MétaCan
Menu
Back to cohort
Record W2078926052 · doi:10.1016/j.bbmt.2007.12.108

99: Predictors of Outcome of Mantle Cell Lymphoma in Patients with Progressive Disease following Autologous Stem Cell Transplantation (ASCT)

2008· article· en· W2078926052 on OpenAlexaff
Khalil Al‐Farsi, Tracy Nagy, Armand Keating, Michael Crump, John Kuruvilla

Bibliographic record

VenueBiology of Blood and Marrow Transplantation · 2008
Typearticle
Languageen
FieldMedicine
TopicLymphoma Diagnosis and Treatment
Canadian institutionsPrincess Margaret Cancer Centre
Fundersnot available
KeywordsMedicineAutologous stem-cell transplantationMantle cell lymphomaInternal medicineOncologyRituximabProportional hazards modelTransplantationProgression-free survivalSurgeryLymphomaChemotherapy

Abstract

fetched live from OpenAlex

Introduction: Mantle Cell Lymphoma (MCL) is a subgroup of malignant lymphomas that is considered incurable with conventional therapy. While ASCT has improved progression free survival (PFS), relapse remains a major issue. For patients (pts) who relapse after ASCT, there is little information on the predictors of outcome and optimal treatment strategy. We reviewed pts with progressive disease following ASCT in an attempt to identify predictors of subsequent outcome. Method: We retrospectively reviewed our computerized database and charts of pts undergoing ASCT from May 1987 - Jul 2006. Of 47 pts, 21 relapsed after ASCT; 20 had adequate data on subsequent therapy and were analyzed for factors influencing progression free survival (PFS) and overall survival (OS) using Kaplan-Meier and Cox-Proportional Hazards analyses. Results: Pt characteristics: At relapse post-ASCT, median age was: 56 years (range 40–69). Stage 3 or 4: 16. High LDH: 8. Disease status of ASCT: CR1/PR1 = 9, >CR1/PR1 = 11. IPI scores: low (n = 9), low-intermediate (n = 8), high-intermediate (n = 2) and high (n = 1). FLIPI scores: low (n = 10), intermediate (n = 4) and high (n = 6). Seven had bone marrow involvement, 3 had involvement of peripheral blood and 5 had splenomegaly. Eighteen pts received subsequent treatment: R-FCM: 4, Rituximab: 1, Radiation alone: 3, other combination chemotherapy: 9 and 1 underwent reduced intensity allogeneic transplantation. Two pts were not fit to receive further treatment and had rapidly progressive disease (PD). Of the treated pts, 6 achieved CR (4 subsequently progressed), 5 PR and 7 had PD. Eleven pts remain alive (only 2 in CR) with PD accounting for all deaths. With a median follow-up of 31 months (m) post relapse for living pts, median PFS from the time of relapse post-ASCT was 5 m and OS was 34 m. No significant predictors of PFS could be identified. For OS, univariate analysis identified time to relapse (TTR; p = 0.011), performance status (PS; p = 0.010) and total IPI score (p = 0.041) as being statistically significant. Only TTR remained significant on the multivariate model. TTR less than 12 months portends a very poor outcome (2 year OS 0% compared to 62% form TTR >12 m; p < 0.001). Conclusion: Pts with MCL who relapse after ASCT do poorly, especially those relapsing within one year of ASCT. New therapeutic approaches incorporating maintenance therapy post-ASCT or the use of novel agents such as bortezomib or mTOR inhibitors should be explored in this group.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.007

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.008
GPT teacher head0.215
Teacher spread0.207 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2008
Admission routes1
Has abstractyes

Explore more

Same venueBiology of Blood and Marrow TransplantationSame topicLymphoma Diagnosis and TreatmentFrench-language works237,207